Skip to main content
Premium Trial:

Request an Annual Quote

Sage Licenses CRISPR-Cas9 Technology from Broad Institute

NEW YORK (GenomeWeb) – Sage Labs today announced it has licensed CRISPR-Cas9 genome editing technology from the Broad Institute.

The license provides Sage the ability to use the technology — for which Broad recently was awarded the first US patent covering the CRISPR-Cas9 technology — to engineer cell and animal models for its clients. Sage will also be able to distribute validated CRISPR reagents, it said. The St. Louis-based company previously licensed CRISPR-Cas9 technology from Caribou Biosciences.

Financial and other terms of the deal were not disclosed.

Sage provides gene editing tools, research models, and support services. While the Broad received the first CRISPR-Cas9 patent, the IP landscape surrounding the technology is becoming increasingly murky, and in a statement Sage CEO David Smoller said that it is crucial that the firm's clients "receive the freedom to operate with their research models, and we're committed to obtaining the necessary licenses."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.